Stéphane Degove
Chief Executive Officer at GamaMabs Pharma SA
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jean-François Prost | M | 71 |
GamaMabs Pharma SA
 GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
| François Thomas | M | 66 |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
| Martine George | M | 76 |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
| Frédéric Revah | M | 62 |
Atamyo Therapeutics SAS
 Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | - |
| Isabelle Richard | F | - |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | 4 years |
| Philippe Boucheron | M | - |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
| Jean-Michel Petit | M | - |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | 11 years |
| Thierry Hercend | M | - |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
| Roger Hajjar | M | - |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | 1 years |
| Alexandre Lemoalle | M | - |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | - |
| Aneta Sottil | F | - |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Béchard | M | - |
Endotis Pharma SARL
 Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | - |
| Charles Woler | M | 74 |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | 6 years |
| Maurice Petitou | M | - |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | 8 years |
| Eric Neuhart | M | - |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | 6 years |
| Patrick Zenner | M | 77 |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | - |
| Peter Hutt | M | 89 |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | - |
| Stephanie Léouzon | F | - |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | - |
| Barbara Williams | F | - |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | - |
| Philippe Lassalle | M | - |
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 20 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stéphane Degove
- Personal Network
